
With our elegant next generation chimeric antigen receptor T (CAR-T) and NK (CAR-NK) platforms and one of the largest portfolios of CAR-T and CAR-NK assets in the world, we have a simple goal: to become the dominant cell therapy company in the world.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.